{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-010872","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.482988+00:00","generated_at":"2026-06-26T00:33:32.511850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DiaMedica reports Q1 2022 cash burn of $3.9M; ReMEDy2 stroke trial sites more than double","bullets":["Cash & investments $41M at March 31 (Dec 31: $45.1M); working capital $40.7M; cash runway into 2024.","Net cash used in ops $3.9M (Q1 2021: $4.3M); R&D exp $2.0M (-$0.4M); G&A exp $1.6M (+$0.4M).","ReMEDy2 stroke trial active sites more than doubled to 9; slower enrollment due to COVID staffing & discharge logistics.","REDUX CKD trial fully enrolled (79 patients); last visit in March 2022; final analysis ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-010872","json":"https://secwatch.observer/filing/0001437749-22-010872.json","markdown":"https://secwatch.observer/filing/0001437749-22-010872.md","text":"https://secwatch.observer/filing/0001437749-22-010872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922010872/0001437749-22-010872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922010872/dmtp20220503_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:33:32.511850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}